EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest

Rasha Kaddoura, Bassant Orabi, Amr S Omar, Mohamed Izham Mohamed Ibrahim, Sumaya Alsaadi Alyafei, Abdulaziz Alkhulaifi, Ahmed Labib Shehatta

Journal of Cardiothoracic and Vascular Anesthesia · 2025

DOI: 10.1053/j.jvca.2025.01.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiothoracic and Vascular Anesthesia, 2025. Verfasst von Rasha Kaddoura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. Electronic address: rasha.kaddoura@gmail.com. Hauptthemen laut MEDLINE: Simendan, Extracorporeal Membrane Oxygenation, Heart Arrest, Cardiotonic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Library, Medical Research Center, Hamad Medical Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To examine whether levosimendan could improve survival in patients with cardiac arrest supported by extracorporeal cardiopulmonary resuscitation (ECPR). DESIGN: A retrospective cohort study. SETTING: Single tertiary academic center. PARTICIPANTS: Patients with refractory cardiac arrest. INTERVENTIONS: Patients who were exposed to levosimendan and those who were not. MEASUREMENT AND MAIN RESULTS: There were 87 patients with a mean age of 45.4 ± 11.9 years, 86.2% of them were males with a mean body mass index of 26.8 ± 5.0 kg/m2, and a mean Charlson Comorbidity Index score of 0.7 ± 1.3. Of the 87 patients, 18 (20.7%) were administered levosimendan. The 2 groups were similar in terms of baseline characteristics. Overall, 70% of patients in both groups suffered in-hospital cardiac arrest and the remaining suffered out of hospital cardiac arrest. Median cardiopulmonary resuscitation duration before extracorporeal membrane oxygenation initiation was 54.0 minutes (interquartile range, 35.0-84.0 minutes). The highest lactate levels after between the second and the fourth days after ECPR were significantly higher (8.1 mmol/L vs 3.4 mmol/L; p = 0.046) and the duration of extracorporeal membrane oxygenation support was significantly longer (4.2 days vs 1.9 days; p = 0.0019) with levosimendan. There was no difference between the groups in terms of survival to decannulation (27.8% vs 26.1%), survival to hospital discharge (27.8% vs 24.6%), length of intensive care unit stay (19.1 vs 18.2 days), length of hospital stay (51.1 days vs 53.4 days), or complications rates (eg, infection, bleeding, and arrhythmias). CONCLUSIONS: Levosimendan use in ECPR did not improve survival. Future well-designed randomized trials are warranted to investigate the potential benefit of levosimendan in the ECPR setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SimendanExtracorporeal Membrane OxygenationHeart ArrestCardiotonic AgentsHumansMaleRetrospective StudiesFemaleMiddle AgedAdultCohort StudiesTreatment OutcomeCardiopulmonary Resuscitation

Stichwörter der Autor:innen

ECMOECPRELSOcardiac arrestcardiopulmonary resuscitationcerebral performance categoryinotropesneurological outcome

Substanzen

SimendanCardiotonic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar. Electronic address: rasha.kaddoura@gmail.com.
  • Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
  • Department of Cardiothoracic Surgery/Cardiac Anesthesia & ICU, Heart Hospital, Hamad Medical Corporation, Doha, Qatar; Weill Cornell Medical College, Doha, Qatar; Department of Critical Care Medicine, Beni Suef Universi…
  • Clinical Pharmacy and Practice Department. College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
  • Department of Cardiothoracic Surgery Heart Hospital, Hamad Medical Corporation, Doha, Qatar; College of Medicine, Qatar University, Doha, Qatar.
  • Weill Cornell Medical College, Doha, Qatar; Medical Intensive Care Unit, Department of Medicine, Hamad General Hospital, Doha Qatar.

Förderung

  • Qatar National Library
  • Medical Research Center, Hamad Medical Corporation

Zitieren

APA

Kaddoura, R., Orabi, B., Omar, A. S., Ibrahim, M. I. M., Alyafei, S. A., Alkhulaifi, A., & Shehatta, A. L. (2025). The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest. Journal of Cardiothoracic and Vascular Anesthesia. https://doi.org/10.1053/j.jvca.2025.01.004

Vancouver

Kaddoura R, Orabi B, Omar AS, Ibrahim MIM, Alyafei SA, Alkhulaifi A, et al. The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest. Journal of Cardiothoracic and Vascular Anesthesia. 2025. doi:10.1053/j.jvca.2025.01.004

BibTeX
@article{Kaddoura2025,
  author = {Kaddoura, Rasha and Orabi, Bassant and Omar, Amr S and Ibrahim, Mohamed Izham Mohamed and Alyafei, Sumaya Alsaadi and Alkhulaifi, Abdulaziz and Shehatta, Ahmed Labib},
  title = {The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest},
  journal = {Journal of Cardiothoracic and Vascular Anesthesia},
  year = {2025},
  doi = {10.1053/j.jvca.2025.01.004}
}
Kostenlos starten →